Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: Immunologic consequences affecting clinical outcome

N. G. Chakraborty, S. Bilgrami, L. J. Maness, C. Guo, A. Perez-Diez, B. Mukherji, P. Tutschka

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Autologous peripheral blood stem cell transplantation following myeloablative chemotherapy is being increasingly utilized in the treatment of a variety of malignancies. We administered busulfan 16 mg/kg orally, thiotepa 500-700 mg/m2 i.v., and carboplatin 800-1000 mg/m2 i.v. to 56 women with metastatic carcinoma of the breast. Autologous peripheral blood stent cells, which had been collected after a combination of chemotherapy and granulocyte colony-stimulating factor, were Infused on day 0. The major toxicities of the conditioning regimen included severe pancytopenia, stomatitis, nausea, emesis, diarrhea, fever, and infection. Transplant-related mortality was 1.8%. The incidence of opportunistic viral infections was 32.9%. Fourteen individuals achieved a complete response. The actuarial survival at 1223 days was 13.7% for the entire group of patients; the actuarial survival at 1009 days was 39.3% among complete responders. The functional status of the immune system was determined following transplantation in a subset of patients. Peripheral blood mononuclear cells were obtained before and after stem cell infusion, and were analyzed phenotypically and functionally. Proliferative and interleukin-2 synthetic ability of these cells was assessed following stimulation with phytohemagglutinin and anti-CD3 antibody. The response to influenza peptides was also ascertained. Proliferative and interleukin-2 synthetic capacity was markedly impaired for over a year. Memory response was virtually absent for up to 2 years following transplantation. The prolonged and marked immunosuppression following this myeloablative regimen was associated with a high incidence of opportunistic viral infections, and may have contributed to disease relapse and progression especially in patients who failed to achieve a complete response following transplantation.

Original languageEnglish (US)
Pages (from-to)837-843
Number of pages7
JournalBone marrow transplantation
Volume24
Issue number8
DOIs
StatePublished - Jan 1 1999

Fingerprint

Peripheral Blood Stem Cell Transplantation
Transplantation
Opportunistic Infections
Virus Diseases
Breast Neoplasms
Drug Therapy
Interleukin-2
Blood Cells
Thiotepa
Artificial Cells
Busulfan
Stomatitis
Pancytopenia
Aptitude
Survival
Carboplatin
Incidence
Phytohemagglutinins
Granulocyte Colony-Stimulating Factor
Combination Drug Therapy

Keywords

  • Breast cancer
  • Immunosuppression
  • Myeloablative chemotherapy
  • Stem cell transplant

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer : Immunologic consequences affecting clinical outcome. / Chakraborty, N. G.; Bilgrami, S.; Maness, L. J.; Guo, C.; Perez-Diez, A.; Mukherji, B.; Tutschka, P.

In: Bone marrow transplantation, Vol. 24, No. 8, 01.01.1999, p. 837-843.

Research output: Contribution to journalArticle

@article{5b2993fc6bf04c61ab096245cdeae976,
title = "Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer: Immunologic consequences affecting clinical outcome",
abstract = "Autologous peripheral blood stem cell transplantation following myeloablative chemotherapy is being increasingly utilized in the treatment of a variety of malignancies. We administered busulfan 16 mg/kg orally, thiotepa 500-700 mg/m2 i.v., and carboplatin 800-1000 mg/m2 i.v. to 56 women with metastatic carcinoma of the breast. Autologous peripheral blood stent cells, which had been collected after a combination of chemotherapy and granulocyte colony-stimulating factor, were Infused on day 0. The major toxicities of the conditioning regimen included severe pancytopenia, stomatitis, nausea, emesis, diarrhea, fever, and infection. Transplant-related mortality was 1.8{\%}. The incidence of opportunistic viral infections was 32.9{\%}. Fourteen individuals achieved a complete response. The actuarial survival at 1223 days was 13.7{\%} for the entire group of patients; the actuarial survival at 1009 days was 39.3{\%} among complete responders. The functional status of the immune system was determined following transplantation in a subset of patients. Peripheral blood mononuclear cells were obtained before and after stem cell infusion, and were analyzed phenotypically and functionally. Proliferative and interleukin-2 synthetic ability of these cells was assessed following stimulation with phytohemagglutinin and anti-CD3 antibody. The response to influenza peptides was also ascertained. Proliferative and interleukin-2 synthetic capacity was markedly impaired for over a year. Memory response was virtually absent for up to 2 years following transplantation. The prolonged and marked immunosuppression following this myeloablative regimen was associated with a high incidence of opportunistic viral infections, and may have contributed to disease relapse and progression especially in patients who failed to achieve a complete response following transplantation.",
keywords = "Breast cancer, Immunosuppression, Myeloablative chemotherapy, Stem cell transplant",
author = "Chakraborty, {N. G.} and S. Bilgrami and Maness, {L. J.} and C. Guo and A. Perez-Diez and B. Mukherji and P. Tutschka",
year = "1999",
month = "1",
day = "1",
doi = "10.1038/sj.bmt.1701999",
language = "English (US)",
volume = "24",
pages = "837--843",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Myeloablative chemotherapy with autologous peripheral blood stem cell transplantation for metastatic breast cancer

T2 - Immunologic consequences affecting clinical outcome

AU - Chakraborty, N. G.

AU - Bilgrami, S.

AU - Maness, L. J.

AU - Guo, C.

AU - Perez-Diez, A.

AU - Mukherji, B.

AU - Tutschka, P.

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Autologous peripheral blood stem cell transplantation following myeloablative chemotherapy is being increasingly utilized in the treatment of a variety of malignancies. We administered busulfan 16 mg/kg orally, thiotepa 500-700 mg/m2 i.v., and carboplatin 800-1000 mg/m2 i.v. to 56 women with metastatic carcinoma of the breast. Autologous peripheral blood stent cells, which had been collected after a combination of chemotherapy and granulocyte colony-stimulating factor, were Infused on day 0. The major toxicities of the conditioning regimen included severe pancytopenia, stomatitis, nausea, emesis, diarrhea, fever, and infection. Transplant-related mortality was 1.8%. The incidence of opportunistic viral infections was 32.9%. Fourteen individuals achieved a complete response. The actuarial survival at 1223 days was 13.7% for the entire group of patients; the actuarial survival at 1009 days was 39.3% among complete responders. The functional status of the immune system was determined following transplantation in a subset of patients. Peripheral blood mononuclear cells were obtained before and after stem cell infusion, and were analyzed phenotypically and functionally. Proliferative and interleukin-2 synthetic ability of these cells was assessed following stimulation with phytohemagglutinin and anti-CD3 antibody. The response to influenza peptides was also ascertained. Proliferative and interleukin-2 synthetic capacity was markedly impaired for over a year. Memory response was virtually absent for up to 2 years following transplantation. The prolonged and marked immunosuppression following this myeloablative regimen was associated with a high incidence of opportunistic viral infections, and may have contributed to disease relapse and progression especially in patients who failed to achieve a complete response following transplantation.

AB - Autologous peripheral blood stem cell transplantation following myeloablative chemotherapy is being increasingly utilized in the treatment of a variety of malignancies. We administered busulfan 16 mg/kg orally, thiotepa 500-700 mg/m2 i.v., and carboplatin 800-1000 mg/m2 i.v. to 56 women with metastatic carcinoma of the breast. Autologous peripheral blood stent cells, which had been collected after a combination of chemotherapy and granulocyte colony-stimulating factor, were Infused on day 0. The major toxicities of the conditioning regimen included severe pancytopenia, stomatitis, nausea, emesis, diarrhea, fever, and infection. Transplant-related mortality was 1.8%. The incidence of opportunistic viral infections was 32.9%. Fourteen individuals achieved a complete response. The actuarial survival at 1223 days was 13.7% for the entire group of patients; the actuarial survival at 1009 days was 39.3% among complete responders. The functional status of the immune system was determined following transplantation in a subset of patients. Peripheral blood mononuclear cells were obtained before and after stem cell infusion, and were analyzed phenotypically and functionally. Proliferative and interleukin-2 synthetic ability of these cells was assessed following stimulation with phytohemagglutinin and anti-CD3 antibody. The response to influenza peptides was also ascertained. Proliferative and interleukin-2 synthetic capacity was markedly impaired for over a year. Memory response was virtually absent for up to 2 years following transplantation. The prolonged and marked immunosuppression following this myeloablative regimen was associated with a high incidence of opportunistic viral infections, and may have contributed to disease relapse and progression especially in patients who failed to achieve a complete response following transplantation.

KW - Breast cancer

KW - Immunosuppression

KW - Myeloablative chemotherapy

KW - Stem cell transplant

UR - http://www.scopus.com/inward/record.url?scp=0032725491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032725491&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1701999

DO - 10.1038/sj.bmt.1701999

M3 - Article

C2 - 10516693

AN - SCOPUS:0032725491

VL - 24

SP - 837

EP - 843

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -